What is MaxCyte's market cap?

MaxCyte (MXCT) has a market capitalization of $137.1M and trades on NASDAQ.

What is MaxCyte's revenue and profitability?

MaxCyte generated $32.3M in trailing twelve-month revenue with a net loss of $39.1M, representing a net margin of -121.2%. Gross margin stands at 80.5%, with free cash flow of -$29.4M. These figures are based on the Q1 2026 filing.

Who are MaxCyte's competitors?

MaxCyte's key competitors include Harvard Biosciences Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and others. These companies compete in similar markets and product categories.

Who does MaxCyte partner with?

MaxCyte's notable partners include Imugene Limited, TG Therapeutics, Inc., National Institutes of Health, and others.

What subsidiaries does MaxCyte have?

MaxCyte's subsidiaries include SeQure Dx.

Where is MaxCyte headquartered?

MaxCyte is headquartered in United States of America and employs approximately 143 people. It has been publicly traded since 2019.

MaxCyte

MXCT

Market cap

$137.12M-43.4%

Revenue$32.3M-14.3%

Net income-$39.1M+6.4%

Free cash flow-$29.4M+10.9%

EPS (diluted)-$0.37+7.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$9.7MBeat by $2.4M EPS-$0.04Beat by $0.06

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$6.6M

EPS estimate-$0.12

Financials

Q1 2026

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation & ratios

Valuation

See full

Market cap$137.12M-43.4%

Enterprise value$140.05M-40.1%

P/S4.3×-2.2×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Segments

By product

See full

License$5.5M+18.2%

Assay And Other Service Revenue$482.0K+21.4%

By segment

See full

Cell Engineering Technology$9.7M-7.1%

Competitors

By market cap

Thermo Fisher Scientific$194.99B+23.4%

TEC

Bio-Techne$11.1B+37.2%

Bio-Rad Laboratories$8.0B+18.3%

Immix Biopharma, Inc.$789.5M+981%

Ginkgo Bioworks$635.6M-4.3%

Protalix BioTherapeutics, Inc.$191.0M+63.2%

MaxCyte$137.1M-40.6%

Harvard Bioscience$28.1M+43.5%

By revenue growth

Thermo Fisher Scientific+2.4%

Bio-Rad Laboratories+1.9%

TEC

Bio-Techne+0.2%

MaxCyte-14.3%

Ginkgo Bioworks-37.8%

By net margin

Thermo Fisher Scientific15.19%+0.4pp

TEC

Bio-Techne10.89%-0.7pp

Bio-Rad Laboratories6.52%+91.7pp

MaxCyte-121.16%-10.2pp

Ginkgo Bioworks-215.41%-7.7pp

Profile

MaxCyte is a commercial cell engineering company that provides proprietary Flow Electroporation technology to enable the discovery, development, and commercialization of next-generation cell-based therapeutics. The company's ExPERT platform serves as a non-viral delivery backbone for gene editing and cell therapy, allowing for the precise introduction of molecules into cells at scales ranging from research to clinical manufacturing. By offering a scalable, high-efficiency transfection solution, the company helps biopharmaceutical partners accelerate the development of complex treatments for cancers, autoimmune diseases, and genetic disorders.

Competitive position

A leading provider of non-viral cell engineering technology with a clinically validated platform supported by an FDA Master File referenced in over 75 clinical trials.

GeographiesNorth America, United Kingdom, Europe, Asia-Pacific

Customer segmentsBiopharmaceutical developers, Academic and translational research centers, cGMP manufacturing facilities

Business modelInstrument sales, Recurring consumables, Technology licensing, Milestone and royalty-based licensing (SPL), Professional services

SuppliersCustom parts manufacturers, Electronics suppliers, Medical-grade plastic and gasket suppliers, Third-party clean-room assembly services

CustomersCell and gene therapy developers, Contract Development and Manufacturing Organizations (CDMOs), Clinical research organizations, Large-scale bioprocessing facilities

CountryUnited States of America

Listed2019

Employees143.0

CEOMaher Masoud

SectorHealthcare

IndustryMedical - Devices

Websitemaxcyte.com

FilingsSEC EDGAR

Ask your AI about MaxCyte.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's market cap?: MaxCyte (MXCT) has a market capitalization of $137.1M and trades on NASDAQ.
What is MaxCyte's revenue and profitability?: MaxCyte generated $32.3M in trailing twelve-month revenue with a net loss of $39.1M, representing a net margin of -121.2%. Gross margin stands at 80.5%, with free cash flow of -$29.4M. These figures are based on the Q1 2026 filing.
Who are MaxCyte's competitors?: MaxCyte's key competitors include Harvard Biosciences Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and others. These companies compete in similar markets and product categories.
Who does MaxCyte partner with?: MaxCyte's notable partners include Imugene Limited, TG Therapeutics, Inc., National Institutes of Health, and others.
What subsidiaries does MaxCyte have?: MaxCyte's subsidiaries include SeQure Dx.
Where is MaxCyte headquartered?: MaxCyte is headquartered in United States of America and employs approximately 143 people. It has been publicly traded since 2019.